7.62
0.21 (2.83%)
| Previous Close | 7.41 |
| Open | 7.36 |
| Volume | 8,181,727 |
| Avg. Volume (3M) | 1,013,729 |
| Market Cap | 377,533,664 |
| Price / Sales | 4.20 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -283.19% |
| Operating Margin (TTM) | -256.55% |
| Diluted EPS (TTM) | -5.01 |
| Quarterly Revenue Growth (YOY) | -16.30% |
| Total Debt/Equity (MRQ) | 48.37% |
| Current Ratio (MRQ) | 3.05 |
| Operating Cash Flow (TTM) | -182.26 M |
| Levered Free Cash Flow (TTM) | -95.26 M |
| Return on Assets (TTM) | -26.03% |
| Return on Equity (TTM) | -71.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | REGENXBIO Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.39% |
| % Held by Institutions | 92.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Integral Health Asset Management, Llc | 30 Sep 2024 | 1,275,000 |
| Aquilo Capital Management, Llc | 30 Sep 2024 | 930,708 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Chardan Capital, 582.42%) | Buy |
| Median | 35.00 (359.32%) | |
| Low | 18.00 (Raymond James, 136.22%) | Buy |
| Average | 32.60 (327.82%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 9.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 11 Dec 2024 | 35.00 (359.32%) | Buy | 9.30 |
| HC Wainwright & Co. | 21 Nov 2024 | 36.00 (372.44%) | Buy | 9.18 |
| 07 Nov 2024 | 40.00 (424.93%) | Buy | 11.19 | |
| Chardan Capital | 20 Nov 2024 | 52.00 (582.41%) | Buy | 9.63 |
| 22 Oct 2024 | 52.00 (582.41%) | Buy | 9.59 | |
| Morgan Stanley | 15 Nov 2024 | 22.00 (188.71%) | Buy | 9.63 |
| Raymond James | 10 Oct 2024 | 18.00 (136.22%) | Buy | 9.29 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |